Want to see OBX full AI Analyst Report?

Obsidian Therapeutics (OBX) Price & Analysis

261 Followers

OBX Stock Chart & Stats

$0.02

<$0.01(0.99%)

At close: Jan 08 4:00 PM EST

$0.02

<$0.01(0.99%)

Day’s Range― - ―

52-Week Range$3.00 - $49.97

Previous CloseN/A

VolumeN/A

Average Volume (3M)63.57K

Market Cap

$18.11M

Enterprise Value$148.50

Total Cash (Recent Filing)$5.50M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)<0.1

Beta1.95

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,040,118

10 Day Avg. Volume87,114

30 Day Avg. Volume63,573

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.33

Price to Sales (P/S)0.00

P/FCF Ratio-0.36

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$42.00

Price Target Upside209900.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Leverage EliminatedRemoving debt and restoring positive equity materially reduces solvency risk and interest obligations, improving financial flexibility. This reset lets management allocate capital to clinical development and operations without near-term creditor pressure, strengthening survival odds through milestone-driven value creation.

Substantial Private Financing & RunwayA $350M private placement provides multi-year runway to reach key clinical readouts (Phase 1 data H1 2027; melanoma topline by year-end 2027). That funding reduces immediate dilution risk, supports manufacturing and trials, and allows execution on strategy without urgent capital raises for 18–24 months.

Clinical/regulatory ProgressAlignment with the FDA on trial design and potency assays and initiation of a registration-enabling cohort materially raises the program's path to accelerated approval. Such regulatory clarity and enrollment progress increase the probability that clinical efforts convert into a viable, approvable product.

Bears Say

Pre-revenue OperationsWith no product revenue, the company remains dependent on financing and successful clinical outcomes to achieve commercial sustainability. Operating profitability and cash generation cannot be assumed until products are approved and adopted, keeping commercialization and execution risk high for the foreseeable term.

Persistent Cash BurnContinued negative operating cash flow and declining free cash flow mean the company relies on external capital to fund operations. If clinical timelines slip or additional costs arise, future fundraising will be necessary and could dilute shareholders or constrain strategic choices despite current runway.

Limited Balance-sheet ScaleA relatively small asset base leaves limited cushion for cost overruns, manufacturing scale-up, or extended trials. Even with recent financing, modest underlying asset scale constrains flexibility for large investments, partnerships, or unexpected liabilities without additional capital or asset sales.

Obsidian Therapeutics News

Zillow downgraded, Global Payments upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1d ago

Obsidian Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Obsidian Therapeutics (OBX) with a Buy rating and no price target The firm...

1d ago

OBX

Best Buy downgraded, Bristol Myers upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2d ago

AZN

BBY

Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause

09:49 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading halted, volatility trading pause Published first on TheFly –...

2d ago

OBX

Obsidian Therapeutics, Inc. Common Stock trading resumes

09:59 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading resumes Published first on TheFly – the ultimate source...

2d ago

OBX

Obsidian announces first patient enrolled in Phase 1/2 Agni-01 study

Obsidian Therapeutics (OBX) announced the first patient has been enrolled in the registration-enabling cohort of the Phase 1/2...

2d ago

OBX

Obsidian Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Obsidian Therapeutics (OBX) with an Overweight rating and...

2d ago

OBX

Obsidian Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Obsidian Therapeutics (OBX) with an Overweight rating and $42 price target Published first...

3d ago

OBX

Obsidian Therapeutics announces closing of transaction with Galera Therapeutics

Obsidian Therapeutics (OBX) announced the completion of its previously announced transaction with Galera Therapeutics (GRTX). The combined company...

3d ago

OBX

Obsidian Therapeutics Completes Merger and Leadership Transition

Obsidian Therapeutics ( ($OBX) ) has shared an update. Following the completion of mergers on August 3, 2026,...

3d ago

OBX

OBX FAQ

What was Obsidian Therapeutics’s price range in the past 12 months?

Obsidian Therapeutics lowest stock price was $3.00 and its highest was $49.97 in the past 12 months.

What is Obsidian Therapeutics’s market cap?

Obsidian Therapeutics’s market cap is $18.11M.

When is Obsidian Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Obsidian Therapeutics’s earnings last quarter?

Currently, no data Available

Is Obsidian Therapeutics overvalued?

According to Wall Street analysts Obsidian Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Obsidian Therapeutics pay dividends?

Obsidian Therapeutics does not currently pay dividends.

What is Obsidian Therapeutics’s EPS estimate?

Obsidian Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Obsidian Therapeutics have?

Obsidian Therapeutics has 1,040,118 shares outstanding.

What happened to Obsidian Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Obsidian Therapeutics?

Currently, no hedge funds are holding shares in OBX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Obsidian Therapeutics

A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.

Obsidian Therapeutics (OBX) Earnings & Revenues

Historic Earnings Reports

OBX Stock 12 Month Forecast

Average Price Target

$42.00

▲(209900.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","13":"$13","23":"$23","33":"$33","43":"$43"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,13,23,33,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.62,17.64923076923077,19.678461538461537,21.707692307692305,23.736923076923077,25.76615384615385,27.795384615384613,29.824615384615385,31.853846153846156,33.88307692307692,35.91230769230769,37.941538461538464,39.97076923076923,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.62,17.64923076923077,19.678461538461537,21.707692307692305,23.736923076923077,25.76615384615385,27.795384615384613,29.824615384615385,31.853846153846156,33.88307692307692,35.91230769230769,37.941538461538464,39.97076923076923,{"y":42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.62,17.64923076923077,19.678461538461537,21.707692307692305,23.736923076923077,25.76615384615385,27.795384615384613,29.824615384615385,31.853846153846156,33.88307692307692,35.91230769230769,37.941538461538464,39.97076923076923,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.6,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.24,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.418,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.5,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.98,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.6,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.62,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >